These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26033044)

  • 1. The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.
    Bachmann HS; Meier W; du Bois A; Kimmig R; Kuhlmann JD; Siffert W; Sehouli J; Wollschlaeger K; Huober J; Hillemanns P; Burges A; Schmalfeldt B; Aminossadati B; Wimberger P
    Br J Clin Pharmacol; 2015 Nov; 80(5):1139-48. PubMed ID: 26033044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
    Kim ES; Kies MS; Fossella FV; Glisson BS; Zaknoen S; Statkevich P; Munden RF; Summey C; Pisters KM; Papadimitrakopoulou V; Tighiouart M; Rogatko A; Khuri FR
    Cancer; 2005 Aug; 104(3):561-9. PubMed ID: 16028213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.
    Meier W; du Bois A; Rau J; Gropp-Meier M; Baumann K; Huober J; Wollschlaeger K; Kreienberg R; Canzler U; Schmalfeldt B; Wimberger P; Richter B; Schröder W; Belau A; Stähle A; Burges A; Sehouli J
    Gynecol Oncol; 2012 Aug; 126(2):236-40. PubMed ID: 22564713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
    Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
    Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Bachmann HS; Jung D; Link T; Arnold A; Kantelhardt E; Thomssen C; Wimberger P; Vetter M; Kuhlmann JD
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
    Borthakur G; Kantarjian H; Daley G; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Faderl S; Sugrue M; Cortes J
    Cancer; 2006 Jan; 106(2):346-52. PubMed ID: 16342165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.
    Ready NE; Lipton A; Zhu Y; Statkevich P; Frank E; Curtis D; Bukowski RM
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):576-83. PubMed ID: 17255280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
    Kieran MW; Packer RJ; Onar A; Blaney SM; Phillips P; Pollack IF; Geyer JR; Gururangan S; Banerjee A; Goldman S; Turner CD; Belasco JB; Broniscer A; Zhu Y; Frank E; Kirschmeier P; Statkevich P; Yver A; Boyett JM; Kun LE
    J Clin Oncol; 2007 Jul; 25(21):3137-43. PubMed ID: 17634493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
    Gordon LB; Shappell H; Massaro J; D'Agostino RB; Brazier J; Campbell SE; Kleinman ME; Kieran MW
    JAMA; 2018 Apr; 319(16):1687-1695. PubMed ID: 29710166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
    Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase inihibitors in hematologic malignancies.
    Harousseau JL
    Blood Rev; 2007 Jul; 21(4):173-82. PubMed ID: 17293017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
    Liu G; Taylor SA; Marrinan CH; Hsieh Y; Bishop WR; Kirschmeier P; Long BJ
    Int J Cancer; 2009 Dec; 125(11):2711-20. PubMed ID: 19530253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lonafarnib for cancer and progeria.
    Wong NS; Morse MA
    Expert Opin Investig Drugs; 2012 Jul; 21(7):1043-55. PubMed ID: 22620979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
    Liu G; Marrinan CH; Taylor SA; Black S; Basso AD; Kirschmeier P; Robert Bishop W; Liu M; Long BJ
    Anticancer Drugs; 2007 Sep; 18(8):923-31. PubMed ID: 17667598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Malig Rep; 2006 Mar; 1(1):20-4. PubMed ID: 20425327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
    Gréen H; Söderkvist P; Rosenberg P; Horvath G; Peterson C
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):854-9. PubMed ID: 16467099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.